Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CDX-585 · 1 trial · 14 indications
The rates of drug-related adverse events will be summarized, and maximum tolerated dose will be determined.
The rates of drug-related adverse events will be summarized, and further evaluated in specific tumor types.
| Arm | Type | Description |
|---|---|---|
| CDX-585 | EXPERIMENTAL | Dose-escalation phase: Eligible patients will receive treatment, based on cohort assigned, in 2-week cycles until progression or intolerance. Expansion phase: Patients enrolled in the expansion phase of the study will receive CDX-585 at the dose level chosen during the escalation phase. |
| Name | Type | Description |
|---|---|---|
| CDX-585 | DRUG | CDX-585 is administered by infusion every 2 weeks |
Key Inclusion Criteria: 1. Recurrent, locally advanced, or metastatic solid tumor cancer excluding primary central nervous system tumors (e.g., glioblastoma). 2. Receipt of standard therapy for the tumor type in the recurrent, locally advanced, or metastatic setting. 3. Measurable (target) disease ...
Top 20 of 84 competitors
CDX-585 is an investigational small molecule being developed for the treatment of non-small cell lung cancer. It is also being studied in other advanced solid tumors, including gastric, head and neck, ovarian, colorectal, and pancreatic cancers. The drug is currently in Phase 1 clinical development.
CDX-585 is being developed by Celldex Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CLDX. The company is conducting clinical trials of CDX-585 in patients with advanced malignancies.
CDX-585 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 study of CDX-585 in patients with advanced malignancies has been completed.
CDX-585 has been studied in a Phase 1 clinical trial with the identifier NCT05788484, titled "A Study of CDX-585 in Patients With Advanced Malignancies." This trial enrolled 20 participants in the United States and included patients with non-small cell lung cancer and other solid tumors.
Yes, CDX-585 is a small molecule therapeutic. It is being developed as an oncology treatment for non-small cell lung cancer and other advanced solid tumors. The drug is currently in Phase 1 clinical trials.